<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPX</journal-id>
<journal-id journal-id-type="hwp">sptpx</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Pathol</journal-id>
<journal-title>Toxicologic Pathology</journal-title>
<issn pub-type="ppub">0192-6233</issn>
<issn pub-type="epub">1533-1601</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0192623312464304</article-id>
<article-id pub-id-type="publisher-id">10.1177_0192623312464304</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Regular Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Toxicology and Carcinogenesis Study of Senna in C3B6.129F1-<italic>Trp53</italic>
<sup>tm1Brd</sup> N12 Haploinsufficient Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Surh</surname>
<given-names>Inok</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464304">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brix</surname>
<given-names>Amy</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464304">1</xref>
<xref ref-type="aff" rid="aff2-0192623312464304">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>French</surname>
<given-names>John E.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464304">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Collins</surname>
<given-names>Bradley J.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464304">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sanders</surname>
<given-names>J. Michael</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464304">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vallant</surname>
<given-names>Molly</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464304">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Dunnick</surname>
<given-names>June K.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312464304">1</xref>
<xref ref-type="corresp" rid="corresp1-0192623312464304"/>
</contrib>
</contrib-group>
<aff id="aff1-0192623312464304"><label>1</label>National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA</aff>
<aff id="aff2-0192623312464304"><label>2</label>Experimental Pathology Laboratories, Inc., Research Triangle Park, North Carolina, USA</aff>
<author-notes>
<corresp id="corresp1-0192623312464304">June K. Dunnick, National Institute of Environmental Health Sciences, P. O. Box 12233, MD K2-13, Research Triangle Park, NC 27709, USA; e-mail: <email>dunnickj@niehs.nih.gov</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>5</issue>
<fpage>770</fpage>
<lpage>778</lpage>
<permissions>
<copyright-statement>© 2012 by The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society of Toxicologic Pathology</copyright-holder>
</permissions>
<abstract>
<p>Senna is a pod or leaf of <italic>Senna alexandrina</italic> P. Mill and is used as a stimulant laxative. In the large intestine, bacterial enzymes reduce sennosides to rhein-9-anthrone, the active form for the laxative effect. To determine the potential toxic effects of senna, a 5-week dose range finding study in the C57BL/6N mouse and a 40-week toxicology and carcinogenesis study in the C3B6.129F1-<italic>Trp53</italic>
<sup>tm1Brd</sup> N12 haploinsufficient (p53<sup>+/−</sup>) mouse were conducted. In the 5-week study, C57BL/6N mice were exposed to up to 10,000 ppm senna in feed. Increased incidences of epithelial hyperplasia of the cecum and colon were observed in males and females exposed to 5,000 or 10,000 ppm senna. These intestinal lesions were not considered to be of sufficient severity to cause mortality and, thus, in the p53<sup>+/−</sup> mouse 40-week study, the high dose of 10,000 ppm was selected. Significant increases in the incidences of epithelial hyperplasia of the colon and cecum were observed at 10,000 ppm in p53<sup>+/−</sup> males and females, and the incidence of hyperplasia of the colon was significantly increased at 3,000 ppm in females. In conclusion, the large intestine was the major target of senna-induced toxicity in both wild-type and the p53<sup>+/−</sup> mouse model. There was no neoplastic change when senna was administered to p53<sup>+/−</sup> mouse. </p>
</abstract>
<kwd-group>
<kwd>senna</kwd>
<kwd>Trp53</kwd>
<kwd>carcinogenesis</kwd>
<kwd>toxicity</kwd>
<kwd>laxative</kwd>
<kwd>large intestine.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0192623312464304">
<title>Introduction</title>
<p>Senna is a pod or leaf of <italic>Senna alexandrina</italic> P. Mill (Leguminosae) (<xref ref-type="bibr" rid="bibr3-0192623312464304">Blumenthal, Goldberg, and Brinckmann 2000</xref>) and is available as over-the-counter laxatives and tea. It is widely used as a stimulant laxative for children and adults, including pregnant women (<xref ref-type="bibr" rid="bibr57-0192623312464304">Smitherman, Janisse, and Mathur 2005</xref>; <xref ref-type="bibr" rid="bibr54-0192623312464304">Shah et al. 2008</xref>; <xref ref-type="bibr" rid="bibr42-0192623312464304">Moussally, Oraichi, and Berard 2009</xref>). In addition, a high dose of senna (3–13 times higher than the recommended dose) is used for cleansing the bowel in preparation for a colonoscopy or surgery (<xref ref-type="bibr" rid="bibr24-0192623312464304">Kleibeuker et al. 1995</xref>; <xref ref-type="bibr" rid="bibr49-0192623312464304">Occhipinti and Di Palma 2009</xref>). The senna plant contains a multitude of chemical components including dianthrones, anthraquinones, naphthalene derivatives, and flavonoids (<xref ref-type="bibr" rid="bibr14-0192623312464304">Franz 1993</xref>). The pharmacological activity of senna is associated with the formation of rhein-9-anthrone (rhein anthrone) from sennosides (<xref ref-type="fig" rid="fig1-0192623312464304">Figure 1</xref>). The sennosides are not readily absorbed from the mammalian gut due to the presence of a β-glycosidic bond, but once they reach the large intestine they are deconjugated and reduced to the active form (rhein anthrone) by microflora (<xref ref-type="bibr" rid="bibr26-0192623312464304">Lemli and Lemmens 1980</xref>; <xref ref-type="bibr" rid="bibr12-0192623312464304">Dreessen, Eyssen, and Lemli 1981</xref>). The laxative effect is driven by increasing peristalsis and reduced absorption of water and electrolytes (<xref ref-type="bibr" rid="bibr27-0192623312464304">Leng-Peschlow 1986</xref>).</p>
<fig id="fig1-0192623312464304" position="float">
<label>Figure 1.</label>
<caption>
<p>Reduction of sennosides A and B to pharmacologically active rhein anthrone by gut microflora and oxidation to rhein. (Adapted from <xref ref-type="bibr" rid="bibr26-0192623312464304">Lemli and Lemmens 1980</xref> and Dreessen, Eyssen, and Lemli 1981.) Glu = glucose.</p>
</caption>
<graphic xlink:href="10.1177_0192623312464304-fig1.tif"/>
</fig>
<p>Most of the published genotoxicity studies with senna reported negative results, but some positive results for senna extracts were reported in bacterial gene mutation test systems as well as in mammalian cells <italic>in vitro </italic>(<xref ref-type="bibr" rid="bibr7-0192623312464304">Brusick and Mengs 1997</xref>). <italic>In vivo</italic>, results of a single study assessing chromosomal damage following treatment with senna extract were negative (<xref ref-type="bibr" rid="bibr35-0192623312464304">Mengs et al. 1999</xref>).  Sennosides, which are major constituents of senna, were generally negative in <italic>in vitro</italic> bacterial mutagenicity tests (<xref ref-type="bibr" rid="bibr34-0192623312464304">Mengs 1988</xref>; <xref ref-type="bibr" rid="bibr51-0192623312464304">Sandnes et al. 1992</xref>; <xref ref-type="bibr" rid="bibr19-0192623312464304">Heidemann, Miltenburger, and Mengs 1993</xref>; <xref ref-type="bibr" rid="bibr20-0192623312464304">Heidemann, Volkner, and Mengs 1996</xref>) and <italic>in vitro</italic> mammalian cell mutagenicity and chromosomal damage assays (<xref ref-type="bibr" rid="bibr34-0192623312464304">Mengs 1988</xref>; <xref ref-type="bibr" rid="bibr51-0192623312464304">Sandnes et al. 1992</xref>; <xref ref-type="bibr" rid="bibr19-0192623312464304">Heidemann, Miltenburger, and Mengs 1993</xref>). Results of chromosomal damage tests in mice yielded mixed results, with one study showing no effect in mice after treatment with mixed sennosides (<xref ref-type="bibr" rid="bibr34-0192623312464304">Mengs 1988</xref>; <xref ref-type="bibr" rid="bibr19-0192623312464304">Heidemann, Miltenburger, and Mengs 1993</xref>) and another showing a small dose-related (<italic>p</italic> &lt; .05) increase in structural chromosomal aberrations in bone marrow cells of mice treated with sennoside B (<xref ref-type="bibr" rid="bibr44-0192623312464304">Mukhopadhyay et al. 1998</xref>). Conflicting results in genotoxicity tests with rhein, a component as well as a metabolite of senna, were observed <italic>in vitro</italic> as well as <italic>in vivo</italic> (<xref ref-type="bibr" rid="bibr66-0192623312464304">Westendorf et al. 1990</xref>; <xref ref-type="bibr" rid="bibr51-0192623312464304">Sandnes et al. 1992</xref>; <xref ref-type="bibr" rid="bibr19-0192623312464304">Heidemann, Miltenburger, and Mengs 1993</xref>; <xref ref-type="bibr" rid="bibr36-0192623312464304">Mengs and Heidemann 1993</xref>; <xref ref-type="bibr" rid="bibr44-0192623312464304">Mukhopadhyay et al. 1998</xref>; <xref ref-type="bibr" rid="bibr31-0192623312464304">Makena and Chung 2007</xref>). Components of certain senna products, particularly the emodin and aloe-emodin compounds, have been shown to be genotoxic <italic>in vitro</italic> (<xref ref-type="bibr" rid="bibr6-0192623312464304">Brown and Dietrich 1979</xref>; <xref ref-type="bibr" rid="bibr66-0192623312464304">Westendorf et al. 1990</xref>; <xref ref-type="bibr" rid="bibr23-0192623312464304">Kawasaki, Goda, and Yoshihira 1992</xref>; <xref ref-type="bibr" rid="bibr51-0192623312464304">Sandnes et al. 1992</xref>; <xref ref-type="bibr" rid="bibr19-0192623312464304">Heidemann, Miltenburger, and Mengs 1993</xref>; <xref ref-type="bibr" rid="bibr43-0192623312464304">Mueller, Stopper, and Dekant 1998</xref>; <xref ref-type="bibr" rid="bibr45-0192623312464304">Nesslany et al. 2009</xref>). </p>
<p>Toxicity of senna has been reported in literature. Subacute exposure to senna (10% senna in diet) resulted in signs of liver and kidney toxicity in rats (<xref ref-type="bibr" rid="bibr1-0192623312464304">Al-Yahya, Al-Farhan, and Adam 2002</xref>). In a subchronic study, reversible hyperplastic changes in the forestomach and the large intestine have been observed in rats (<xref ref-type="bibr" rid="bibr37-0192623312464304">Mengs et al. 2004</xref>). In human, case studies of hepatitis and allergic reactions associated with excessive use of senna have been reported (<xref ref-type="bibr" rid="bibr2-0192623312464304">Beuers, Spengler, and Pape 1991</xref>; <xref ref-type="bibr" rid="bibr32-0192623312464304">Marks, Salome, and Woolcock 1991</xref>; <xref ref-type="bibr" rid="bibr21-0192623312464304">Helin and Makinen-Kiljunen 1996</xref>; <xref ref-type="bibr" rid="bibr59-0192623312464304">Spiller et al. 2003</xref>; <xref ref-type="bibr" rid="bibr53-0192623312464304">Seybold et al. 2004</xref>; <xref ref-type="bibr" rid="bibr65-0192623312464304">Vanderperren et al. 2005</xref>). Sennosides increased colonic epithelial cell proliferation in humans (<xref ref-type="bibr" rid="bibr24-0192623312464304">Kleibeuker et al. 1995</xref>; <xref ref-type="bibr" rid="bibr64-0192623312464304">van Gorkom et al. 2000</xref>). </p>
<p>Studies reported in the literature suggest that there may be an association between laxative use and colon cancer in humans (<xref ref-type="bibr" rid="bibr56-0192623312464304">Siegers et al. 1993</xref>; <xref ref-type="bibr" rid="bibr52-0192623312464304">Satia et al. 2009</xref>). For example, findings from an epidemiology study revealed that more patients with gastrointestinal cancer were senna users than patients without cancer and patients without gastrointestinal disease (<xref ref-type="bibr" rid="bibr5-0192623312464304">Boyd and Doll 1954</xref>). However, the relationship between senna use and colon cancer has not been clearly demonstrated. Experimental animal models have not been able to resolve this association between senna use and cancer. Several studies showed senna or sennosides did not affect incidences of neoplastic lesions (<xref ref-type="bibr" rid="bibr30-0192623312464304">Lyden-Sokolowski, Nilsson, and Sjoberg 1993</xref>; <xref ref-type="bibr" rid="bibr55-0192623312464304">Siegers, Siemers, and Baretton 1993</xref>; <xref ref-type="bibr" rid="bibr4-0192623312464304">Borrelli et al. 2005</xref>; <xref ref-type="bibr" rid="bibr39-0192623312464304">Mitchell et al. 2006</xref>). However, in the literature senna extract or sennosides have been shown to increase tumor formation (<xref ref-type="bibr" rid="bibr38-0192623312464304">Mereto, Ghia, and Brambilla 1996</xref>; <xref ref-type="bibr" rid="bibr33-0192623312464304">Mascolo et al. 1999</xref>).</p>
<p>The <italic>p53</italic> tumor suppressor gene suppresses cancer in both humans and mice. The p53 protein is critical to cell cycle control, DNA repair, and apoptosis, and is often mutated or lost in human and rodent cancers (<xref ref-type="bibr" rid="bibr58-0192623312464304">Soussi and Beroud 2001</xref>; <xref ref-type="bibr" rid="bibr68-0192623312464304">Zuckerman et al. 2009</xref>). The haploinsufficient <italic>Trp53 </italic>tumor suppressor gene mouse model heterozygous for a wild-type and null (+/−) <italic>Trp53 </italic>alleles (<xref ref-type="bibr" rid="bibr10-0192623312464304">Donehower et al. 1992</xref>, <xref ref-type="bibr" rid="bibr11-0192623312464304">1995</xref>) was used in these studies. This Trp53 protein haploinsufficient mouse model has been extensively tested as a short-term cancer bioassay mouse model (<xref ref-type="bibr" rid="bibr60-0192623312464304">Tennant, French, and Spalding 1995</xref>; <xref ref-type="bibr" rid="bibr13-0192623312464304">Dunnick et al. 1997</xref>; <xref ref-type="bibr" rid="bibr16-0192623312464304">French, Storer, and Donehower 2001</xref>; <xref ref-type="bibr" rid="bibr18-0192623312464304">French et al. 2001</xref>; <xref ref-type="bibr" rid="bibr50-0192623312464304">Pritchard et al. 2003</xref>; <xref ref-type="bibr" rid="bibr17-0192623312464304">French 2004</xref>) based upon the observation that mice with only a single wild-type <italic>Trp</italic>53 allele show a significant decrease in the time required for genotoxic carcinogen-induced tumors to develop. These tumors are often associated with either a mutation and/or a loss of heterozygosity of the remaining wild-type <italic>Trp53 </italic>allele. Few to no sporadic tumors occur in concurrent or historical study control groups in this model during the in-life exposures up to 45-46 weeks of age, which allows tests to be conducted with fewer animals and direct analysis of the target wild-type <italic>Trp53 </italic>allele for mutation or loss of heterozygosity <italic>in vivo </italic>as a mode of action. Genetically altered mouse models have been shown to be useful for detecting carcinogenic activity of genotoxic chemicals (<xref ref-type="bibr" rid="bibr50-0192623312464304">Pritchard et al. 2003</xref>), which is the basis for use of an alternative mouse model. In addition, the B6.129-<italic>Trp53</italic>
<sup>tm1Brd</sup> haploinsuficient model has tested positive for colorectal tumors induced by azoxymethane and dimethylhydrazine (<xref ref-type="bibr" rid="bibr29-0192623312464304">Lubet et al. 2000</xref>; <xref ref-type="bibr" rid="bibr22-0192623312464304">Hu, Le Leu, and Young 2005</xref>; <xref ref-type="bibr" rid="bibr40-0192623312464304">Mladenova et al. 2011</xref>).</p>
<p>Laxative use is widespread in the United States and there is concern about potential toxicity from long-term use, including commonly used products containing senna (<xref ref-type="bibr" rid="bibr63-0192623312464304">U.S. Food and Drug Administration 1999</xref>). Additional characterization of the toxic potential of senna is needed for risk assessment in humans. Therefore, we conducted toxicological and carcinogenicity studies of senna in the C3B6.129F1-<italic>Trp53</italic>
<sup>tm1Brd</sup> haploinsufficient mouse model. </p>
</sec>
<sec id="section2-0192623312464304" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-0192623312464304">
<title>Chemicals</title>
<p>Senna was obtained from Madaus AG (Köln, Germany) in one lot (1999000).  Senna was identified by chromatographic comparisons to purchased reference standards using two high-performance liquid chromatography with ultraviolet detection (HPLC/UV) analytical systems. Weight percentages of active components were estimated: 0.7% sennoside A, 1.3% sennoside B, 0.06% sennidin A, and 0.03% sennidin B. The senna was sterilized by exposure to cobalt-60 ionizing radiation. Comparison of the irradiated material with the nonirradiated material indicated that all 10 major peaks present in the nonirradiated material were present in the irradiated material at a relative concentration of ≥90.7%. Examination of the chromatograms before and after irradiation indicated no differences in significant peaks.</p>
</sec>
<sec id="section4-0192623312464304">
<title>Animals</title>
<p>Male and female C57BL/6NTac mice as well as male and female C3B6.129F1-<italic>Trp53</italic>
<sup>tm1Brd</sup> N12 haploinsufficient (p53<sup>+/−</sup>) mice, heterozygous for a wild-type and null allele, were obtained from Taconic Farms, Inc. (Germantown, NY). Mice were quarantined for at least 6 days and housed individually during the studies. NTP-2000 diet (Zeigler Brothers, Inc. Gardners, PA) and water were available <italic>ad libitum</italic>. The care of animals in this study was according to NIH procedures as described in the “The U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals” (<xref ref-type="bibr" rid="bibr46-0192623312464304">NIH 2002</xref>).</p>
<p>An outcross between C3H/HeNTac (C3, Taconic Model P53N12-M) female mice homozygous for the wild-type <italic>Trp53</italic> allele and the congenic C57BL/6.129Sv-<italic>Trp53</italic>
<sup>tm1Brd</sup> N12 (abbreviated B6.129-<italic>Trp53</italic>
<sup>tm1Brd</sup>) N12 (Model P53N12-M) backcross generation males (homozygous for the <italic>Trp53</italic> null allele) produced congenic C3B6.129F1-<italic>Trp53</italic>
<sup>Tm1Brd</sup> N12 progeny, Taconic Laboratory Animals and Sciences (Germantown, NY). The N12 backcross generation was selected in order to reduce tumor penetrance variability observed in the N5 generation model used in the International Life Sciences Institute/Health and Environmental Sciences Institute (ILSI/HESI) alternative mouse model studies (unpublished result/John E. French, NIEHS/NTP). <italic>Trp53</italic> null mutation was introduced by homologous recombination in AB1 murine embryonic stem cells, which were derived from a black agouti 129Sv inbred mouse. By targeted insertion of a <italic>pol</italic>II neo cassette, an engineered null mutation was induced as a result of the deletion of a 450-base pair gene fragment from the <italic>Trp53</italic> gene that included 106 nucleotides of exon 5 and approximately 350 nucleotides of intron 4 that eliminated both mRNA and p53 protein expression from this allele (<xref ref-type="bibr" rid="bibr10-0192623312464304">Donehower et al. 1992</xref>, <xref ref-type="bibr" rid="bibr11-0192623312464304">1995</xref>).</p>
</sec>
<sec id="section5-0192623312464304">
<title>Five-Week Study</title>
<p>Groups of 5 male and 5 female C57BL/6NTac mice at 6 to 7 weeks of age were used. NTP-2000 diets containing 0, 625, 1,250, 2,500, 5,000, or 10,000 ppm senna were provided <italic>ad libitum</italic> for 29 days.  Feed consumption was recorded weekly by animal. Clinical findings were recorded weekly. The animals were weighed initially, weekly, and at the end of the study. At the end of the study, carbon dioxide was used to euthanize animals. At necropsy, organ weights were recorded for the heart, right kidney, liver, lung, right testis, and thymus.  Histopathologic examinations were performed on all mice.</p>
</sec>
<sec id="section6-0192623312464304">
<title>Forty-Week Study</title>
<p>Groups of 25 male and 25 female p53<sup>+/−</sup> mice at 6 to 8 weeks of age were used. NTP-2000 diets containing 0, 100, 300, 1,000, 3,000 or 10,000 ppm senna were provided <italic>ad libitum</italic> for 40 weeks. Feed consumption was recorded weekly by animal. Clinical findings were recorded weekly. The animals were weighed initially, weekly, and at the end of the study. At the end of the study, carbon dioxide was used to euthanize animals. At necropsy, all organs were fixed in 10% neutral-buffered formalin, processed, and stained with hematoxylin and eosin (H&amp;E) for histological examination. </p>
</sec>
<sec id="section7-0192623312464304">
<title>Pathology</title>
<p>Hyperplasia of the large intestinal mucosa was graded similarly in the 5-week and 40-week studies.  In the colon, normal crypt depth in controls was up to 175 µm. Colonic hyperplasia was graded based upon crypt depth, as follows:  in minimal (grade 1) hyperplasia, crypt depth was approximately 200 µm (from basement membrane to surface of crypt epithelium, measured where an entire crypt was in longitudinal section) but only focally or multifocally; in mild (grade 2) hyperplasia, crypt depth was ≥200 µm over much of the circumference and was focally approximately 300 to 350 µm; in moderate (grade 3) hyperplasia almost the entire circumference of the section examined was involved with crypts 300 to 350 µm deep. The same criteria were used for the cecum but due to the naturally thicker mucosa found in the rectum severity grading for the rectum was done more subjectively.</p>
</sec>
<sec id="section8-0192623312464304">
<title>Statistical Analysis</title>
<p>The Fisher exact test was used to determine statistical differences in incidences of lesions between treatment groups.</p>
</sec>
</sec>
<sec id="section9-0192623312464304">
<title>Results</title>
<sec id="section10-0192623312464304">
<title>Five-Week Study in C57BL/6NTac Mice</title>
<p>A 5-week study was designed to investigate toxicological effects of senna in C57BL/6NTac mice. All mice survived to the end of the study. Final mean body weights of all exposed groups were within 5% of the controls. Feed consumption by exposed groups was similar to that by the controls. Concentrations of 625, 1,250, 2,500, 5,000, and 10,000 ppm senna in feed resulted in average daily doses of 115, 245, 490, 975, and 2,075 mg senna/kg body weight to males and 160, 310, 625, 1,190, and 2,570 mg/kg to females. There were no apparent treatment-related clinical findings. Significant decreases in absolute heart weights occurred in all exposed groups of males. Relative heart weights were significantly decreased in 625, 5,000, and 10,000 ppm males.</p>
<p>Exposure to senna resulted in epithelial hyperplasia of the cecum and colon in males and of the cecum, colon, and rectum in females (<xref ref-type="table" rid="table1-0192623312464304">Table 1</xref> and <xref ref-type="fig" rid="fig2-0192623312464304">Figure 2</xref>). A no-observed-effect level (NOEL) could not be determined for the male mice because the 625 ppm group had two mice with minimal hyperplasia of the cecum, and one animal in the 1,250 ppm group had hyperplasia of the cecum and colon. The NOEL for female mice was 1,250 ppm based upon the lack of lesions in that group and the presence of two animals in the 2,500 ppm group with cecal hyperplasia and one with hyperplasia of the colon. The hyperplasia was characterized by a thickening of the mucosa by increased depth of the crypts (<xref ref-type="fig" rid="fig2-0192623312464304">Figure 2</xref>). This was due to increased numbers of epithelial cells, which were small, with basophilic cytoplasm and round to oval nuclei, which became more vesicular toward the luminal surface of the glands. Goblet cells were interspersed within these cells but did not constitute an increased proportion of the epithelial cells in the colon or cecum. Mitotic figures were numerous.</p>
<fig id="fig2-0192623312464304" position="float">
<label>Figure 2.</label>
<caption>
<p>Colon from the 5-week study of senna. (A), A section of colon from a control female mouse;  25×, hemotoxylin and eosin (H&amp;E).  (B), A section of colon with moderate hyperplasia from a female mouse exposed to 10,000 ppm senna. The depths of the crypts and the number of epithelial cells are increased, as evidenced by crowding, increased basophilia, and increased mitotic figures; 25×, H&amp;E. </p>
</caption>
<graphic xlink:href="10.1177_0192623312464304-fig2.tif"/>
</fig>
<table-wrap id="table1-0192623312464304" position="float">
<label>Table 1.</label>
<caption>
<p>Final mean body weight, heart weight, and incidences of hyperplasia in the large intestine of C57BL/6NTac mice in the 5-week feed study of senna.</p>
</caption>
<graphic alternate-form-of="table1-0192623312464304" xlink:href="10.1177_0192623312464304-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Dose (ppm)</th>
<th rowspan="2">Final weight relative to controls (%)</th>
<th rowspan="2">Heart Weight</th>
<th>Cecum</th>
<th>Colon</th>
<th>Rectum</th>
</tr>
<tr>
<th>Epithelial hyperplasia</th>
<th>Epithelial hyperplasia</th>
<th>Epithelial hyperplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">Male</td>
</tr>
<tr>
<td> 0</td>
<td>
</td>
<td>0.15 ± 0.01</td>
<td>0<sup>a</sup>
</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 625</td>
<td>99</td>
<td>0.13 ± 0.00<sup>&amp;</sup>
</td>
<td>2(1.0)<sup>b</sup>
</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 1,250</td>
<td>96</td>
<td>0.13 ± 0.01<sup>&amp;</sup>
</td>
<td>1(1.0)</td>
<td>1(1.0)</td>
<td>0</td>
</tr>
<tr>
<td> 2,500</td>
<td>99</td>
<td>0.13 ± 0.01<sup>&amp;</sup>
</td>
<td>1(1.0)</td>
<td>1(1.0)</td>
<td>0</td>
</tr>
<tr>
<td> 5,000</td>
<td>99</td>
<td>0.13 ± 0.01<sup>&amp;</sup>
</td>
<td>3(1.0)</td>
<td>4*(1.3)</td>
<td>0</td>
</tr>
<tr>
<td> 10,000</td>
<td>96</td>
<td>0.12 ± 0.00<sup>&amp;</sup>
</td>
<td>5**(1.8)</td>
<td>5**(2.0)</td>
<td>0</td>
</tr>
<tr>
<td colspan="5">Female</td>
</tr>
<tr>
<td> 0</td>
<td>
</td>
<td>0.12 ± 0.00</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 625</td>
<td>95</td>
<td>0.12 ± 0.01</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 1,250</td>
<td>99</td>
<td>0.12 ± 0.00</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 2,500</td>
<td>100</td>
<td>0.13 ± 0.01</td>
<td>2(1.0)</td>
<td>1(1.0)</td>
<td>0</td>
</tr>
<tr>
<td> 5,000</td>
<td>94</td>
<td>0.13 ± 0.01</td>
<td>4*(1.0)</td>
<td>5**(1.4)</td>
<td>0</td>
</tr>
<tr>
<td> 10,000</td>
<td>96</td>
<td>0.11 ± 0.00</td>
<td>5**(1.8)</td>
<td>5**(3.0)</td>
<td>3(1.0)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0192623312464304">
<p>
<italic>Note:</italic> <italic>N</italic> = 5.</p>
</fn>
<fn id="table-fn2-0192623312464304">
<p>
<sup>&amp;</sup>Significantly different (<italic>p</italic> ≤ .01) from the control group by Williams' or Dunnett’s test.</p>
</fn>
<fn id="table-fn3-0192623312464304">
<p>*Significantly different (<italic>p</italic> ≤ .05) from the control group by the Fisher exact test.</p>
</fn>
<fn id="table-fn4-0192623312464304">
<p>**<italic>p</italic> ≤ .01.</p>
</fn>
<fn id="table-fn5-0192623312464304">
<p>
<sup>a</sup> Number of animals with lesion.</p>
</fn>
<fn id="table-fn6-0192623312464304">
<p>
<sup>b</sup> Average severity grade of lesions in affected animals: 1 = <italic>minimal</italic>, 2 = <italic>mild</italic>, 3 = <italic>moderate</italic>, 4 = <italic>marked</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0192623312464304">
<title>40-Week Study in p53<sup>+/−</sup> Mice</title>
<p>A 40-week study was conducted to investigate the toxic and/or carcinogenic potential of senna in p53<sup>+/−</sup> mice. In the 5-week study in C57BL/6NTac mice, no effect on survival or body weights was observed. In addition, intestinal lesions were not considered to be of a sufficient severity to cause mortality in a 40-week study in p53<sup>+/−</sup> mice. Therefore, the high dose of 10,000 ppm was selected. Due to increased sensitivity in p53<sup>+/−</sup> mice and increased duration of exposure, a broader range of exposure (0, 100, 300, 1,000, 3,000, and 10,000 ppm) was selected for the 40-week study. </p>
<p>Survival of all exposed groups was similar to that of the control groups (Table 2). Mean body weights of exposed male and female mice were within 10% of those of the controls throughout the study. Feed consumption by exposed mice was generally similar to that by the controls throughout the study. Concentrations of 100, 300, 1,000, 3,000, and 10,000 ppm in feed resulted in average daily doses of 12, 36, 120, 365, and 1,260 mg/kg to males and 14, 42, 140, 435, and 1,520 mg/kg to females. There were no apparent exposure-related clinical findings. The absolute and relative liver weights of 10,000 ppm males were significantly less than those of the controls. </p>
<p>Significant increases in the incidences of epithelial hyperplasia of the colon and cecum occurred in 10,000 ppm males and females, and the incidence of hyperplasia of the colon was significantly increased in 3,000 ppm females (<xref ref-type="table" rid="table2-0192623312464304">Table 2</xref>, <xref ref-type="fig" rid="fig3-0192623312464304">Figures 3</xref> and <xref ref-type="fig" rid="fig4-0192623312464304">4</xref>). Three 3,000 ppm males had epithelial hyperplasia of the colon and single occurrences of epithelial hyperplasia of the rectum were recorded in the 10,000 ppm males and females; although lacking statistical significance, these lesions are considered biologically noteworthy. The changes were characterized by a thickening of the mucosa by a lengthening of the crypts (<xref ref-type="fig" rid="fig3-0192623312464304">Figures 3</xref> and <xref ref-type="fig" rid="fig4-0192623312464304">4</xref>). This was due to increased numbers of epithelial cells that appeared crowded together. These cells were small and had basophilic cytoplasm and round to oval nuclei, which became more vesicular toward the luminal surface of the glands. Goblet cells were interspersed with these cells but did not constitute an increased proportion of the epithelial cells in the colon or cecum. Mitotic figures were numerous. The cecum was usually less severely affected than the colon.</p>
<fig id="fig3-0192623312464304" position="float">
<label>Figure 3.</label>
<caption>
<p>Colon from the 40-week study of senna. (A), A cross-section of the colon from a control male mouse; 3×, hemotoxylin and eosin (H&amp;E). (B), A cross-section of the colon from a male p53<sup>+/−</sup> mouse exposed to 10,000 ppm.  There is moderate epithelial hyperplasia, with diffuse thickening of the epithelium. 3×, H&amp;E. (C), Higher magnification of colonic epithelium from a control male mouse. 20×, H&amp;E. (D), a section of colon from a male mouse exposed to 10,000 ppm senna. The epithelium is thickened as evidenced by increased distance from the luminal surface to the base of the crypts.  Epithelial cells are increased in number and are basophilic and crowded, the cells lack the orderly arrangement seen in the control mouse, and there are numerous mitotic figures (arrows); 20×, H&amp;E.  </p>
</caption>
<graphic xlink:href="10.1177_0192623312464304-fig3.tif"/>
</fig>
<fig id="fig4-0192623312464304" position="float">
<label>Figure 4.</label>
<caption>
<p>Cecum from the 40-week study of senna. (A), Low magnification of the cecum from a control male; 2.3×, hemotoxylin and eosin (H&amp;E). (B), Cecum from a male mouse exposed to 10,000 ppm senna. There is moderate hyperplasia; the epithelium of the cecum is diffusely thickened in the treated animal when compared to the control animal; 2.3×, H&amp;E.</p>
</caption>
<graphic xlink:href="10.1177_0192623312464304-fig4.tif"/>
</fig>
<table-wrap id="table2-0192623312464304" position="float">
<label>Table 2.</label>
<caption>
<p>Survial, final mean body weights and incidences of hyperplasia in the large intestine of p53<sup>+/−</sup> mice in the 40-week feed study of senna.</p>
</caption>
<graphic alternate-form-of="table2-0192623312464304" xlink:href="10.1177_0192623312464304-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Dose (ppm)</th>
<th rowspan="2">Survival<sup>a</sup>
</th>
<th rowspan="2">Final weight relative to controls (%)</th>
<th>Cecum</th>
<th>Colon</th>
<th>Rectum</th>
</tr>
<tr>
<th>Epithelial hyperplasia</th>
<th>Epithelial hyperplasia</th>
<th>Epithelial hyperplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">Male</td>
</tr>
<tr>
<td> 0</td>
<td>25/25</td>
<td>
</td>
<td>0/25<sup>b</sup>
</td>
<td>0/25</td>
<td>0/24</td>
</tr>
<tr>
<td> 100</td>
<td>24/25</td>
<td>101</td>
<td>0/25</td>
<td>0/25</td>
<td>0/25</td>
</tr>
<tr>
<td> 300</td>
<td>25/25</td>
<td>104</td>
<td>0/25</td>
<td>0/25</td>
<td>0/25</td>
</tr>
<tr>
<td> 1,000</td>
<td>25/25</td>
<td>98</td>
<td>0/25</td>
<td>0/25</td>
<td>0/25</td>
</tr>
<tr>
<td> 3,000</td>
<td>23/25</td>
<td>101</td>
<td>0/23</td>
<td>3/24(1.3)</td>
<td>0/24</td>
</tr>
<tr>
<td> 10,000</td>
<td>24/25</td>
<td>95</td>
<td>22/25*(1.4)<sup>c</sup>
</td>
<td>25/25*(2.8)</td>
<td>1/25(2.0)</td>
</tr>
<tr>
<td colspan="5">Female</td>
</tr>
<tr>
<td> 0</td>
<td>23/25</td>
<td>
</td>
<td>0/25</td>
<td>0/25</td>
<td>0/25</td>
</tr>
<tr>
<td> 100</td>
<td>23/25</td>
<td>99</td>
<td>0/25</td>
<td>0/25</td>
<td>0/25</td>
</tr>
<tr>
<td> 300</td>
<td>23/25</td>
<td>96</td>
<td>0/25</td>
<td>0/25</td>
<td>0/25</td>
</tr>
<tr>
<td> 1,000</td>
<td>22/25</td>
<td>99</td>
<td>0/25</td>
<td>0/25</td>
<td>0/25</td>
</tr>
<tr>
<td> 3,000</td>
<td>22/25</td>
<td>97</td>
<td>0/25</td>
<td>7/25*(1.0)</td>
<td>0/25</td>
</tr>
<tr>
<td> 10,000</td>
<td>24/25</td>
<td>93</td>
<td>19/25*(1.3)</td>
<td>25/25*(2.7)</td>
<td>1/25(1.0)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0192623312464304">
<p>*Significantly different (<italic>p</italic> ≤ .01) from the control group by the Fisher exact test.</p>
</fn>
<fn id="table-fn8-0192623312464304">
<p>
<sup>a</sup> Number of animals surviving at 40 weeks/number initially in group.</p>
</fn>
<fn id="table-fn9-0192623312464304">
<p>
<sup>b</sup> Number of animals with lesion.</p>
</fn>
<fn id="table-fn10-0192623312464304">
<p>
<sup>c</sup> Average severity grade of lesions in affected animals: 1 = <italic>minimal</italic>, 2 = <italic>mild</italic>, 3 = <italic>moderate</italic>, 4 = <italic>marked</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Osteosarcomas occurred in 1,000 and 3,000 ppm males but not in the control group; the incidences in these groups were within the historical control range (<xref ref-type="table" rid="table3-0192623312464304">Table 3</xref>). In 1,000 ppm females, the incidence of osteosarcoma exceeded the historical control range by one tumor but was not significantly greater than the incidence in the concurrent control group.  Osteosarcomas in the mice were found in various sites, including femur (one male and one female), maxilla (four males and two females), rib (one female), tibia (one female), vertebra (one male and four females), and unspecified (one female). The incidence of hepatocellular adenoma in 300 ppm males was increased, which exceeded the historical control range but not significantly (<xref ref-type="table" rid="table3-0192623312464304">Table 3</xref>).  The biological relevance of these findings is unknown.</p>
<table-wrap id="table3-0192623312464304" position="float">
<label>Table 3.</label>
<caption>
<p>Incidences of osteosarcoma and hepatocellular adenoma in p53<sup>+/−</sup> mice in the 40-week feed study of senna.</p>
</caption>
<graphic alternate-form-of="table3-0192623312464304" xlink:href="10.1177_0192623312464304-table3.tif"/>
<table>
<thead>
<tr>
<th>Dose (ppm)</th>
<th>Osteosarcoma</th>
<th>Hepatocellular adenoma</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2">Male</td>
</tr>
<tr>
<td> 0</td>
<td>0<sup>a</sup>
</td>
<td>1<sup>c</sup>
</td>
</tr>
<tr>
<td> 100</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 300</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td> 1,000</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td> 3,000</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td> 10,000</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td colspan="2">Female</td>
</tr>
<tr>
<td> 0</td>
<td>2<sup>b</sup>
</td>
<td>0</td>
</tr>
<tr>
<td> 100</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td> 300</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td> 1,000</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td> 3,000</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> 10,000</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0192623312464304">
<p>
<italic>Note:</italic> <italic>N</italic> = 25.</p>
</fn>
<fn id="table-fn12-0192623312464304">
<p>
<sup>a</sup> Historical incidence for control groups in 9-month p53<sup>+/−</sup> mouse studies: 5/77, range 0–12%.</p>
</fn>
<fn id="table-fn13-0192623312464304">
<p>
<sup>b</sup> Historical incidence for control groups in 9-month p53<sup>+/−</sup> mouse studies: 3/76, range 0–8%.</p>
</fn>
<fn id="table-fn14-0192623312464304">
<p>
<sup>c</sup> Historical incidence for control groups in 9-month p53<sup>+/−</sup> mouse studies: 5/76, range 4–12%.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section12-0192623312464304">
<title>Discussion</title>
<p>The daily senna exposure concentrations in the current studies overlapped with daily exposures in humans taking senna in laxative preparations. In the 40-week study, based on the percentage total weight values for sennosides A and B (approximately 2% of senna by weight), the sennosides A and B consumption was approximately 0.24, 0.72, 2.4, 7.3, or 25.4 mg/kg or 0.72, 2.2, 7.2, 21.9, or 76.1 mg/m<sup>3</sup> (on a body surface area basis) per day in males (<xref ref-type="bibr" rid="bibr15-0192623312464304">Freireich et al. 1966</xref>). Senna consumption by females was similar to that by males. For a typical over-the-counter senna laxative preparation taken twice daily, the amount of sennosides consumed is approximately 1.4 mg/kg per day or 51.8 mg/m<sup>3</sup> (body surface area basis) per day (<xref ref-type="bibr" rid="bibr47-0192623312464304">Novartis 2010</xref>). In some cases, laxatives may be taken in greater than recommended amounts (<xref ref-type="bibr" rid="bibr9-0192623312464304">Cance, Ashley, and Penne 2005</xref>; <xref ref-type="bibr" rid="bibr8-0192623312464304">Bryant-Waugh et al. 2006</xref>; <xref ref-type="bibr" rid="bibr41-0192623312464304">Mond et al. 2006</xref>; <xref ref-type="bibr" rid="bibr62-0192623312464304">Tozzi et al. 2006</xref>). </p>
<p>Senna had a laxative effect in rats receiving daily doses of 300 mg/kg or greater by oral gavage for 13 consecutive weeks (<xref ref-type="bibr" rid="bibr37-0192623312464304">Mengs et al. 2004</xref>). Also, senna extract or sennosides had a laxative effect in rats (<xref ref-type="bibr" rid="bibr30-0192623312464304">Lyden-Sokolowski, Nilsson, and Sjoberg 1993</xref>; <xref ref-type="bibr" rid="bibr61-0192623312464304">Toyoda et al. 1994</xref>; <xref ref-type="bibr" rid="bibr33-0192623312464304">Mascolo et al. 1999</xref>). However, in the current studies no laxative effect was observed at comparable or higher doses in mice, possibly indicating species-dependent differences in sensitivity or kinetics in the formation of rhein anthrone, primarily responsible for the purgative activity of senna (<xref ref-type="bibr" rid="bibr28-0192623312464304">Leng-Peschlow 1992</xref>; <xref ref-type="bibr" rid="bibr67-0192623312464304">Yamauchi, Yagi, and Kuwano 1993</xref>). Additionally, a vehicle effect cannot be ruled out due to possible interaction of sennoside-derived species with the feed particles.  Rhein anthrone is formed by intestinal bacteria at the site of action and is purportedly metabolized through a free radical (<xref ref-type="bibr" rid="bibr26-0192623312464304">Lemli and Lemmens 1980</xref>; <xref ref-type="bibr" rid="bibr12-0192623312464304">Dreessen, Eyssen, and Lemli 1981</xref>; <xref ref-type="bibr" rid="bibr25-0192623312464304">Lemli 1988</xref>), a possible mechanism in the formation of the intestinal hyperplastic response observed at the high dose in the current studies. </p>
<p>Significant decrease in heart weights was observed from the 5-week study. However, no gross lesions were found in heart tissues. In the 40-week study, there was no change in heart weights or no treatment-related lesions in the heart. Therefore, decrease in heart weight was not considered treatment related. In the 40-week study, there were changes recorded in the liver weights (reduction in the mean absolute and relative liver weight in the 10,000 ppm males and an increase in the relative liver weight in the 10,000 ppm females), but the incidences of chronic active inflammation, or any other lesion in the liver, could not explain the liver weight changes.</p>
<p>There were increases in the incidences of osteosarcoma in 1,000 and 3,000 males. However, the incidences were within historical control range. Increased incidence of osteosarcoma in 1,000 females was not significantly increased but greater than the historical control range. Increased incidence of hepatocellular adenoma in 300 ppm males exceeded the historical control range, but not significantly. Therefore, increased incidences of osteosarcoma and hepatocellular adenoma were not considered as treatment-related finding.</p>
<p>Treatment-related epithelial hyperplasia in the large intestine occurred in both the 5-week senna study in C57BL/6NTac mice and in the 40-week senna study in p53<sup>+/−</sup> mice. These results are consistent with other rodent studies. In rats receiving up to 0.05% sennoside A in feed for 7 days, a dose-dependent increase in proliferation index in the large intestine (cecum and colorectum) was observed (<xref ref-type="bibr" rid="bibr61-0192623312464304">Toyoda et al. 1994</xref>). However, in contrast to our results, inflammatory changes (neutrophilic leukocytes infiltration and crypt abscess formation) were observed in that study. In rats receiving up to 1,500 mg/kg senna for 13 weeks, minimal to slight hyperplastic changes in the mucosa of the large intestine in rats receiving more than 100 mg/kg of senna were observed. These hyperplastic lesions were not observed after 8 weeks of recovery period (<xref ref-type="bibr" rid="bibr37-0192623312464304">Mengs et al. 2004</xref>). Also, in rats receiving 25, 100, or 300 mg/kg senna for 2 years, dose-dependent, minimal to slight mucosal epithelial hyperplasia of the large intestine (colon and cecum) was observed (<xref ref-type="bibr" rid="bibr39-0192623312464304">Mitchell et al. 2006</xref>). In addition, in human, 2 mg/kg sennoside A and B administration increased the proliferative index in the large intestine (cecum, colon, and rectum; <xref ref-type="bibr" rid="bibr64-0192623312464304">van Gorkom et al. 2000</xref>). </p>
<p>In agreement with our results, exposure to senna, senna extract, or sennosides to rodents in previous studies was not associated with tumor formation.  <xref ref-type="bibr" rid="bibr39-0192623312464304">Mitchell et al. (2006</xref>) conducted a 2-year oral gavage study of senna in Sprague-Dawley rats (0, 25, 100, or 300 mg/kg/day). There were no treatment-related carcinogenic effects in any target organ and there was only a slight intestinal hyperplasia in the treated groups in that study. In another 2-year study in Sprague-Dawley rats administered a senna extract (reported to contain up to 35% to 42% sennosides) in drinking water (to deliver 0, 5, 15, or 25 mg/kg/day of the test article), no intestinal lesions were observed in treated or control groups (<xref ref-type="bibr" rid="bibr30-0192623312464304">Lyden-Sokolowski, Nilsson, and Sjoberg 1993</xref>). Also, administration of 30 or 60 mg/kg senna extract by oral gavage (six times per week) for 110 weeks in male Wistar rats did not induce aberrant crypt foci or tumors (<xref ref-type="bibr" rid="bibr4-0192623312464304">Borrelli et al. 2005</xref>). <xref ref-type="bibr" rid="bibr33-0192623312464304">Mascolo et al. (1999</xref>) showed that a laxative-producing dose of senna pod extract (10 mg/kg) administered to male Wistar rats for 13 to 28 weeks did not promote the formation of tumors induced by azoxymethane. In addition, a diet containing 0.03% sennoside fed to male NMRI mice for 20 weeks with concurrent administration of dimethylhydrazine (20 mg/kg, subcutaneous) for 10 weeks did not promote the formation of colorectal tumors (<xref ref-type="bibr" rid="bibr55-0192623312464304">Siegers, Siemers, and Baretton 1993</xref>). The numbers and multiplicities of aberrant crypt foci were not affected in dimethylhydrazine-treated male Sprague-Dawley rats fed a 0.1% sennoside-containing diet (<xref ref-type="bibr" rid="bibr38-0192623312464304">Mereto, Ghia, and Brambilla 1996</xref>).</p>
<p>Results of NTP bacterial mutagenicity tests with senna and some of its constituents (sennosides, rhein, and chrysophanic acid) were mixed, with some samples giving negative results and others, including rhein and the senna sample used in the 40-week mouse study, giving positive results (<xref ref-type="bibr" rid="bibr48-0192623312464304">NTP 2011</xref>). Despite the observed activity with some of these compounds <italic>in vitro</italic>, results of the <italic>in vivo</italic> mouse peripheral blood micronucleus test with senna were negative, a result that is consistent with the results of the 40-week bioassay (<xref ref-type="bibr" rid="bibr48-0192623312464304">NTP 2011</xref>). </p>
<p>In contrast to our result, a diarrhea-producing dose (100 mg/kg, by gavage) of senna pod extract administered for 13 weeks to rats increased the incidence and multiplicity of tumors induced by azoxymethane (<xref ref-type="bibr" rid="bibr33-0192623312464304">Mascolo et al. 1999</xref>). In addition, Sprague-Dawley rats fed a diarrhea-inducing level of sennoside in the diet (0.2%) exhibited a significantly increased number of crypts/foci compared to controls (<xref ref-type="bibr" rid="bibr38-0192623312464304">Mereto, Ghia, and Brambilla 1996</xref>). However, oral administration of 30 or 60 mg/kg senna pod extract for 2 years to male Wistar rats treated with the initiating agent azoxymethane (7.5 mg/kg, intraperitoneal) decreased the formation of aberrant crypt foci and colon tumors compared to animals that received azoxymethane alone (<xref ref-type="bibr" rid="bibr4-0192623312464304">Borrelli et al. 2005</xref>).</p>
<p>In conclusion, the major effect of senna administered in feed to mice was a dose-related increase in the incidence of intestinal epithelial hyperplasia. There was no neoplastic change in this experimental situation, when senna was administered to p53<sup>+/−</sup> mouse; however, it remains to be determined whether the observance of senna-induced intestinal hyperplasia in rodents indicates potential risk to senna-exposed humans.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This article may be the work product of an employee or group of employees of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). However, the statements, opinions, or conclusions contained therein do not necessarily represent the statements, opinions, or conclusions of NIEHS, NIH, or the U.S. government. We greatly acknowledge the expert review by Ms. Kristine Witt and Dr. Arun Pandiri. The in life phase of the study was conducted under NIEHS contracts N01-ES-65406 and N01-ES-55536. The authors would like to thank Drs. Milton Hejtmancik, Diane Gerken, Daphne Vasconcelos, and other staff at Battelle Memorial Institute for helping to conduct these studies. </p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0192623312464304">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0192623312464304">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Yahya</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Al-Farhan</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>S. E.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Toxicological interactions of Cassia senna and Nerium oleander in the diet of rats</article-title>. <source>Am J Chin Med</source> <volume>30</volume>, <fpage>579</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr2-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beuers</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Spengler</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Pape</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Hepatitis after chronic abuse of senna</article-title>. <source>Lancet</source> <volume>337</volume>, <fpage>372</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr3-0192623312464304">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Blumenthal</surname>
<given-names>M.,</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>A.,</given-names>
</name>
<name>
<surname>Brinckmann</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Herbal Medicine: Expanded Commission E Monographs</article-title>. pp. <fpage>341</fpage>–<lpage>45</lpage>. <publisher-loc>Austin, TX</publisher-loc>: <publisher-name>American Botanical Council</publisher-name>. </citation>
</ref>
<ref id="bibr4-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borrelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Capasso</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Aviello</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Di Carlo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Izzo</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Mascolo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Capasso</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Senna and the formation of aberrant crypt foci and tumors in rats treated with azoxymethane</article-title>. <source>Phytomedicine</source> <volume>12</volume>, <fpage>501</fpage>–<lpage>505</lpage>; <comment>discussion 505</comment>.</citation>
</ref>
<ref id="bibr5-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyd</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Doll</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>1954</year>). <article-title>Gastro-intestinal cancer and the use of liquid paraffin</article-title>. <source>Br J Cancer</source> <volume>8</volume>, <fpage>231</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr6-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>P. S.</given-names>
</name>
</person-group> (<year>1979</year>). <article-title>Mutagenicity of anthraquinone and benzanthrone derivatives in the Salmonella/microsome test: Activation of anthraquinone glycosides by enzymic extracts of rat cecal bacteria</article-title>. <source>Mutat Res</source> <volume>66</volume>, <fpage>9</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr7-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brusick</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mengs</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Assessment of the genotoxic risk from laxative senna products</article-title>. <source>Environ Mol Mutagen</source> <volume>29</volume>, <fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr8-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bryant-Waugh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>East</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gamble</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Misuse of laxatives among adult outpatients with eating disorders: Prevalence and profiles</article-title>. <source>Int J Eat Disord</source> <volume>39</volume>, <fpage>404</fpage>–<lpage>409</lpage>.</citation>
</ref>
<ref id="bibr9-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cance</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Ashley</surname>
<given-names>O. S.</given-names>
</name>
<name>
<surname>Penne</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Unhealthy weight control behaviors and MDMA (Ecstasy) use among adolescent females</article-title>. <source>J Adolesc Health</source> <volume>37</volume>, <fpage>409</fpage>.</citation>
</ref>
<ref id="bibr10-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donehower</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Slagle</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>C. A.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Butel</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title>. <source>Nature</source> <volume>356</volume>, <fpage>215</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr11-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donehower</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>McArthur</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>C. A.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Park</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Effects of genetic background on tumorigenesis in p53-deficient mice</article-title>. <source>Mol Carcinog</source> <volume>14</volume>, <fpage>16</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr12-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dreessen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eyssen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lemli</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1981</year>). <article-title>The metabolism of sennosides A and B by the intestinal microflora: In vitro and in vivo studies on the rat and the mouse</article-title>. <source>J Pharm Pharmacol</source> <volume>33</volume>, <fpage>679</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr13-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunnick</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Hardisty</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Seely</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Furedi-Machacek</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Lacks</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Stasiewicz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/−) mice</article-title>. <source>Toxicol Pathol</source> <volume>25</volume>, <fpage>533</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr14-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franz</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>The senna drug and its chemistry</article-title>. <source>Pharmacology</source>, <volume>47</volume> <issue>Suppl 1</issue>, <fpage>2</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr15-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freireich</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Gehan</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Rall</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Skipper</surname>
<given-names>H. E.</given-names>
</name>
</person-group> (<year>1966</year>). <article-title>Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man</article-title>. <source>Cancer Chemother Rep</source> <volume>50</volume>, <fpage>219</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr16-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Storer</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Donehower</surname>
<given-names>L. A.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens</article-title>. <source>Toxicol Pathol</source> <volume>29</volume> <issue>Suppl</issue>, <fpage>24</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr17-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus</article-title>. <source>IARC Sci Publ</source> <volume>2004</volume>, <fpage>271</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr18-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Lacks</surname>
<given-names>G. D.</given-names>
</name>
<name>
<surname>Trempus</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dunnick</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mahler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tice</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Tennant</surname>
<given-names>R. W.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/−) mouse tumors is carcinogen-and tissue-dependent</article-title>. <source>Carcinogenesis</source> <volume>22</volume>, <fpage>99</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr19-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heidemann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miltenburger</surname>
<given-names>H. G.</given-names>
</name>
<name>
<surname>Mengs</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>1993</year>). T<article-title>he genotoxicity status of senna</article-title>. <source>Pharmacology</source> <volume>47</volume> <issue>Suppl 1</issue>, <fpage>178</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr20-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heidemann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Volkner</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mengs</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Genotoxicity of aloeemodin in vitro and in vivo</article-title>. <source>Mutat Res</source> <volume>367</volume>, <fpage>123</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr21-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Makinen-Kiljunen</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Occupational asthma and rhinoconjunctivitis caused by senna</article-title>. <source>Allergy</source> <volume>51</volume>, <fpage>181</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr22-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Le Leu</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>G. P.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Absence of acute apoptotic response to genotoxic carcinogens in p53-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours</article-title>. <source>Int J Cancer</source> <volume>115</volume>, <fpage>561</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr23-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Goda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshihira</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>The mutagenic constituents of Rubia tinctorum</article-title>. <source>Chem Pharm Bull (Tokyo)</source> <volume>40</volume>, <fpage>1504</fpage>–<lpage>09</lpage>.</citation>
</ref>
<ref id="bibr24-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleibeuker</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Cats</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zwart</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mulder</surname>
<given-names>N. H.</given-names>
</name>
<name>
<surname>Hardonk</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>E. G.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides</article-title>. <source>J Natl Cancer Inst</source> <volume>87</volume>, <fpage>452</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr25-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemli</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Metabolism of sennosides--an overview</article-title>. <source>Pharmacology</source> <volume>36</volume> <fpage>Suppl</fpage> 1, <fpage>126</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr26-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemli</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lemmens</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1980</year>). <article-title>Metabolism of sennosides and rhein in the rat</article-title>. <source>Pharmacology</source> <volume>20</volume> <issue>Suppl 1</issue>, <fpage>50</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr27-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leng-Peschlow</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>1986</year>). <article-title>Dual effect of orally administered sennosides on large intestine transit and fluid absorption in the rat</article-title>. <source>J Pharm Pharmacol</source> <volume>38</volume>, <fpage>606</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr28-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leng-Peschlow</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Senna and its rational use</article-title>. <source>Pharmacology</source> <volume>44</volume> <issue>Suppl 1</issue>, <fpage>1</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr29-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lubet</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wiseman</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Use of p53 transgenic mice in the development of cancer models for multiple purposes</article-title>. <source>Exp Lung Res</source> <volume>26</volume>, <fpage>581</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr30-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyden-Sokolowski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sjoberg</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Two-year carcinogenicity study with sennosides in the rat: Emphasis on gastro-intestinal alterations</article-title>. <source>Pharmacology</source> <volume>47</volume> <issue>Suppl 1</issue>, <fpage>209</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr31-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makena</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>K. T.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Effects of various plant polyphenols on bladder carcinogen benzidine-induced mutagenicity</article-title>. <source>Food Chem Toxicol</source> <volume>45</volume>, <fpage>1899</fpage>–<lpage>909</lpage>.</citation>
</ref>
<ref id="bibr32-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marks</surname>
<given-names>G. B.</given-names>
</name>
<name>
<surname>Salome</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Woolcock</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Asthma and allergy associated with occupational exposure to ispaghula and senna products in a pharmaceutical work force</article-title>. <source>Am Rev Respir Dis</source> <volume>144</volume>, <fpage>1065</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr33-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mascolo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mereto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Borrelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Orsi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Izzo</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Massa</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Boggio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Capasso</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Does senna extract promote growth of aberrant crypt foci and malignant tumors in rat colon?</article-title> <source>Dig Dis Sci</source> <volume>44</volume>, <fpage>2226</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr34-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mengs</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Toxic effects of sennosides in laboratory animals and in vitro</article-title>. <source>Pharmacology</source> <volume>36</volume> <issue>Suppl 1</issue>, <fpage>180</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr35-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mengs</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Grimminger</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Krumbiegel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schuler</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Silber</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Volkner</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>No clastogenic activity of a senna extract in the mouse micronucleus assay</article-title>. <source>Mutat Res</source> <volume>444</volume>, <fpage>421</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr36-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mengs</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Heidemann</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Genotoxicity of sennosides and rhein in vitro and in vivo</article-title>. <source>Med Sci Res</source> <volume>21</volume>, <fpage>749</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr37-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mengs</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gregson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tigner</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>A 13-week oral toxicity study of senna in the rat with an 8-week recovery period</article-title>. <source>Arch Toxicol</source> <volume>78</volume>, <fpage>269</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr38-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mereto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ghia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Evaluation of the potential carcinogenic activity of Senna and Cascara glycosides for the rat colon</article-title>. <source>Cancer Lett</source> <volume>101</volume>, <fpage>79</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr39-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Mengs</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zijlstra</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dettmar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gregson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tigner</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>An oral carcinogenicity and toxicity study of senna (Tinnevelly senna fruits) in the rat</article-title>. <source>Arch Toxicol</source> <volume>80</volume>, <fpage>34</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr40-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mladenova</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Dahlstrom</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Bean</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pickford</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Currey</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Musgrove</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Kohonen-Corish</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon</article-title>. <source>Gut</source> <volume>60</volume>, <fpage>350</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr41-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mond</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Rodgers</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Correlates of self-induced vomiting and laxative misuse in a community sample of women</article-title>. <source>J Nerv Ment Dis</source> <volume>194</volume>, <fpage>40</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr42-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moussally</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Oraichi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Berard</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Herbal products use during pregnancy: prevalence and predictors</article-title>. <source>Pharmacoepidemiol Drug Saf</source> <volume>18</volume>, <fpage>454</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr43-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>S. O.</given-names>
</name>
<name>
<surname>Stopper</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dekant</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Biotransformation of the anthraquinones emodin and chrysophanol by cytochrome P450 enzymes. Bioactivation to genotoxic metabolites</article-title>. <source>Drug Metab Dispos</source> <volume>26</volume>, <fpage>540</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr44-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukhopadhyay</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dutta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Genotoxicity of sennosides on the bone marrow cells of mice</article-title>. <source>Food Chem Toxicol</source> <volume>36</volume>, <fpage>937</fpage>–<lpage>940</lpage>.</citation>
</ref>
<ref id="bibr45-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nesslany</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Simar-Meintieres</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ficheux</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Marzin</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Aloe-emodin-induced DNA fragmentation in the mouse in vivo comet assay</article-title>. <source>Mutat Res</source> <volume>678</volume>, <fpage>13</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr46-0192623312464304">
<citation citation-type="book">
<collab collab-type="author">National Institutes of Health (U.S.). Office of Laboratory Animal Welfare</collab> (<year>2002</year>). <article-title>Public health service policy on humane care and use of laboratory animals</article-title>. <publisher-loc>Office of laboratory animal welfare, National Institutes of Health, Department of Health and Human Services, Bethesda, MD</publisher-loc>.</citation>
</ref>
<ref id="bibr47-0192623312464304">
<citation citation-type="web">
<collab collab-type="author">Novartis</collab>. (<year>2010</year>). <comment>Accessed on March 17, 2010</comment>. <article-title>Product informatoin for ex-lax maximum strength</article-title>. <ext-link ext-link-type="uri" xlink:href="http://ex-lax.com/product-max.shtml">http://ex-lax.com/product-max.shtml</ext-link>.</citation>
</ref>
<ref id="bibr48-0192623312464304">
<citation citation-type="web">
<collab collab-type="author">NTP</collab>. (<year>2011</year>). <comment>Accessed January 11, 2012</comment>. <ext-link ext-link-type="uri" xlink:href="http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?searchterm=senna&amp;fuseaction=ntpsearch.searchresults">http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?searchterm=senna&amp;fuseaction=ntpsearch.searchresults</ext-link>.</citation>
</ref>
<ref id="bibr49-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Occhipinti</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Di Palma</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>How to choose the best preparation for colonoscopy</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> <volume>6</volume>, <fpage>279</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr50-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pritchard</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Haseman</surname>
<given-names>J. K.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The role of transgenic mouse models in carcinogen identification</article-title>. <source>Environ Health Perspect</source> <volume>111</volume>, <fpage>444</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr51-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandnes</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Johansen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Teien</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ulsaker</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Mutagenicity of crude senna and senna glycosides in <italic>Salmonella typhimurium</italic>
</article-title>. <source>Pharmacol Toxicol</source> <volume>71</volume>, <fpage>165</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr52-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Satia</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Littman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Slatore</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Galanko</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>18</volume>, <fpage>1419</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr53-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seybold</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Landauer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hillebrand</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goebel</surname>
<given-names>F. D.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Senna-induced hepatitis in a poor metabolizer</article-title>. <source>Ann Intern Med</source> <volume>141</volume>, <fpage>650</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr54-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>Chitkara</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Locke</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Meek</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Talley</surname>
<given-names>N. J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Ambulatory care for constipation in the United States, 1993-2004</article-title>. <source>Am J Gastroenterol</source> <volume>103</volume>, <fpage>1746</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr55-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegers</surname>
<given-names>C. P.</given-names>
</name>
<name>
<surname>Siemers</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Baretton</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Sennosides and aloin do not promote dimethylhydrazine-induced colorectal tumors in mice</article-title>. <source>Pharmacology</source> <volume>47</volume> <issue>Suppl 1</issue>, <fpage>205</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr56-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegers</surname>
<given-names>C. P.</given-names>
</name>
<name>
<surname>von Hertzberg-Lottin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Otte</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Anthranoid laxative abuse--a risk for colorectal cancer?</article-title> <source>Gut</source> <volume>34</volume>, <fpage>1099</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr57-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smitherman</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Janisse</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mathur</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>The use of folk remedies among children in an urban black community: Remedies for fever, colic, and teething</article-title>. <source>Pediatrics</source> <volume>115</volume>, <fpage>e297</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr58-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soussi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Beroud</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Assessing TP53 status in human tumours to evaluate clinical outcome</article-title>. <source>Nat Rev Cancer</source> <volume>1</volume>, <fpage>233</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr59-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spiller</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Winter</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Krenzelok</surname>
<given-names>E. P.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>M. L.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Skin breakdown and blisters from senna-containing laxatives in young children</article-title>. <source>Ann Pharmacother</source> <volume>37</volume>, <fpage>636</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr60-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tennant</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Spalding</surname>
<given-names>J. W.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models</article-title>. <source>Environ Health Perspect</source> <volume>103</volume>, <fpage>942</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr61-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toyoda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nishikawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Furukawa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kawanishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Cell proliferation induced by laxatives and related compounds in the rat intestine</article-title>. <source>Cancer Lett</source> <volume>83</volume>, <fpage>43</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr62-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tozzi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fichter</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Klump</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Lilenfeld</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Reba</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Strober</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaye</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Bulik</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Features associated with laxative abuse in individuals with eating disorders</article-title>. <source>Psychosom Med</source> <volume>68</volume>, <fpage>470</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr63-0192623312464304">
<citation citation-type="journal">
<collab collab-type="author">U.S. Food and Drug Administration</collab>. (<year>1999</year>). <article-title>Laxative Drug Products for Over-the Counter Human Use</article-title>. <source>Federal Register</source> <volume>64</volume>, <fpage>4535</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr64-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Gorkom</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Karrenbeld</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>van Der Sluis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Koudstaal</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>E. G.</given-names>
</name>
<name>
<surname>Kleibeuker</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Influence of a highly purified senna extract on colonic epithelium</article-title>. <source>Digestion</source> <volume>61</volume>, <fpage>113</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr65-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanderperren</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Angenot</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Haufroid</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jadoul</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hantson</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides</article-title>. <source>Ann Pharmacother</source> <volume>39</volume>, <fpage>1353</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr66-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westendorf</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marquardt</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Poginsky</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dominiak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Genotoxicity of naturally occurring hydroxyanthraquinones</article-title>. <source>Mutat Res</source> <volume>240</volume>, <fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr67-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamauchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yagi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kuwano</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Suppression of the purgative action of rhein anthrone, the active metabolite of sennosides A and B, by calcium channel blockers, calmodulin antagonists and indomethacin</article-title>. <source>Pharmacology</source> <volume>47</volume> <issue>Suppl 1</issue>, <fpage>22</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr68-0192623312464304">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuckerman</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Wolyniec</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sionov</surname>
<given-names>R. V.</given-names>
</name>
<name>
<surname>Haupt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Haupt</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Tumour suppression by p53: The importance of apoptosis and cellular senescence</article-title>. <source>J Pathol</source> <volume>219</volume>, <fpage>3</fpage>–<lpage>15</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>